Scholars Central

Conference abstractPublished 7 Dec 2018

Resistance to tyrosine kinase-targeted therapy in lung cancer: Autophagy and metabolic changes

Authors: Olivier E Pardo

Imperial College London, UK

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Tyrosine-kinase inhibitors (TKI) are novel agents in the treatment of lung cancer, the commonest cancer killer worldwide. However, their efficacy is impaired by the rapid development of drug-resistance through various mechanisms. Here, we will discuss resistance to first-generation EGFR inhibitors (e.g. Erlotinib) and SRC inhibitors (e.g. Dasatinib). The principal mechanism of resistance to first-generation EGFR inhibitors is the appearance of the T790M receptor mutation. Our metabolomics analysis revealed that resistance is associated with decreased cellular levels of glutathione (GSH), a direct consequence of the T790M mutation. This occurred because of decreased SQSTM1/NRF2-mediated transcription of GSH synthesizing enzymes in cell lines and clinical samples. Increasing GSH levels in resistant cells re-sensitizes these to firstgeneration EGFR inhibitors in vitro and in vivo. As compounds exist in the clinic to achieve this, our finding may have profound therapeutic implications. Src family kinases (SFK) are commonly overexpressed or hyperactivated in lung cancer cell lines and clinical samples. However, despite their on-target efficacy, SRC inhibitors have failed to prevent tumor growth and improve patientsâ?? survival in multiple clinical trials. Here we show that this failure is associated with the induction of autophagy in treated cells that prevents these compounds from triggering apoptosis cell death. Targeting autophagy, either genetically or using our novel small-molecule inhibitor, C1A sensitizes lung cancer cell lines to Dasatinib both in vitro and in vivo by unlocking the apoptotic response. These findings propose new combinational therapeutic strategies that could resurrect the use of SRC inhibitors in the treatment of lung cancer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Oncology Translational Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Oncology Translational Research
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Olivier E Pardo”